由于近期进入冬季流感高发期，市场关注度持续提升，新华制药此前两个交易日连续走高。公开资料显示，该公司是全球重要的解热镇痛药物供应商，拥有布洛芬、阿司匹林、五安系列、美洛昔康等系列产品。2024年前三季度，山东新华制药股份取得营业收入人民币67.34亿元(单位下同)，同比增加3.64%；归属于上市公司股东的净利润3.44亿元，同比减少12.22%。SHANDONG XINHUA (00719) AH Stocks have fallen by over 6%, after experiencing two consecutive days of strength. As of the time of writing, A Shares have decreased by 6.24%, and H Shares have fallen by 6.76%, trading at 5.93 Hong Kong dollars, with a transaction value of 51.139 million Hong Kong dollars.
According to Zhito Finance APP, SHANDONG XINHUA (00719) AH Stocks fell over 6%, having previously risen for two consecutive trading days. As of the time of writing, A Shares fell 6.24%, H Shares fell 6.76%, reported at 5.93 Hong Kong dollars, with a transaction volume of 51.139 million Hong Kong dollars.
On January 6th, news emerged that SHANDONG XINHUA announced that the closing price increase of its A Shares on January 3rd and January 6th had a cumulative deviation of 20% over two consecutive trading days. According to the relevant regulations of the Shenzhen Stock Exchange, this constitutes an abnormal fluctuation in stock trading. The company's Board of Directors confirmed that there are currently no undisclosed matters in accordance with the Shenzhen Stock Exchange's Listing Rules or related plans, discussions, intentions, or agreements regarding this matter.
Due to the recent onset of the winter flu season, market attention has been continually rising, with Shandong Xinhua Pharmaceutical having increased for two consecutive trading days. Public information shows that the company is a Global major supplier of antipyretic and analgesic medication, with a product range that includes Ibuprofen, Aspirin, and Meloxicam among others. For the first three quarters of 2024, SHANDONG XINHUA achieved revenue of 6.734 billion yuan (same unit), an increase of 3.64% year-on-year; the Net income attributable to Shareholders of the listed company was 0.344 billion yuan, a decrease of 12.22% year-on-year.
